Fredun Pharmaceuticals has informed that the Board of Directors of the company, at their Meeting held on Friday, 27th January, 2023 had considered and approved the following item: In compliance to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Un-Audited Financial Results of the Company for the quarter ended 31st December 2022 along with the Limited Review Report as issued by Savla & Associates, Statutory Auditors of the Company; copies of which are attached. The Meeting of the Board Commenced at 2.00 pm and concluded at 08:00 pm.
The above information is a part of company’s filings submitted to BSE.
